Kyu Jun Son, MD

-Freelance consultant for new product planning, competitive intelligence, and forecasting

Global Brand Lead for the Basal Cell Carcinoma and Cervical Cancer indications for Libtayo - Led global marketing initiatives for the launch of the basal cell carcinoma indication for Libtayo, including core messaging and design of the core visual aid - Scientific data interpretation, framing, and messaging - Led global roll out of the Basal Cell Carcinoma marketing campaign to LATAM and Europe - Cross functional collaboration with country teams to understand local market dynamics and needs for global level support

New Product Planning and Business Development Forecasting, and Commercial Assessments for Oncology • Act as the commercial voice for early R&D and clinical teams to develop and refine clinically meaningful development plans that maximize the value of programs • Create global forecasts and analysis for business development including a successful $2.5B acquisition • Collect insights to create global revenue forecasts for oncology assets in preclinical to late clinical development, as part of a cross functional team consisting of New Product Planning, Regulatory Affairs, Value and Access, Pricing, Market Research, Competitive Intelligence, and Research and Development • Assess competitive positioning of pipeline assets relative to established and in development competitors, market access landscape, pricing, and disease area overviews for R&D and clinical development teams • Utilize commercial, treatment practice, and epidemiological data to ensure integration of commercial priorities into early development of oncology assets and business development opportunities • Coordinate with Market Research and consulting vendors to generate insights into clinical, access, patients, providers, and payer perspectives for internal and external assets • Synthesize and present strategic insights and revenue forecasts to executive leadership at the Oncology business unit and C-suite level to guide therapeutic area and company strategy • Created internal guidance for the development of oncology companion diagnostics to address increasing role of precision medicine in current and future treatment of patients • Developed early brand launch strategy with an agency of record for SERD SAR439859 • Maintain up to date understanding of scientific, clinical, commercial, and regulatory landscape in oncology

Global Oncology Forecasting for Libtayo (cemiplimab), Sarclisa (isatuximab), Business Development, and New Product Planning • Develop and maintain revenue forecasts for the entire Sanofi Genzyme Oncology portfolio at the Global level for New Product Planning (NPP), Business Development (BD), cemiplimab, and isatuximab • Create standardized market models for cemiplimab and isatuximab based on Global brand lead input and market and regional level feedback, and led the training and the distribution process for the models • Produce revenue forecasts for Oncology development teams in pre-proof of concept to phase II trials • Coordinate with a cross functional new product planning and business development team to lead collection of primary scientific literature, market research, and competitive intelligence data for assets of strategic interest • Produce presentations and revenue forecasts for executive leadership at the Oncology business unit and executive leadership team level • Present to Oncology executive leadership and work closely with leadership to identify and address knowledge gaps in clinical and commercial data • Collaborate with commercial leadership for key go/no-go decisions around opportunities and guide overall discussion around strategic fit of opportunities into the broader Sanofi Oncology Portfolio • Participate in key business development discussions with outside companies at the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) meetings • Lead competitive intelligence coverage for business development and new product planning at ASCO and ASH • Provided clinical and commercial feedback on rare disease business development opportunity

• Support oncology market research, business development, and new products • Developed and operationalized standardized oncology market models for global distribution across all Sanofi markets integrating cross functional stakeholder feedback for Libtayo and isatuximab • Supported creation of financial guidance issued to countries regarding forecasting for Libtayo and isatuximab • Perform due diligence on pharmaceutical companies with oncology assets

• Worked directly with the Director of Sanofi New Products and Commercial Strategy • Performed competitive intelligence on oncology pharmaceuticals • Performed due diligence on companies in the oncology market • Independently developed financial forecast models to assess commercial viability of internal and external oncology pharmaceutical assets with review and feedback by manager • Researched scientific studies to support commercial assessment of products • Produced and presented analysis of data to multiple teams within the company and to the chief commercial officer • Executed scientific, commercial, and primary market research of oncology assets for business development • Worked with and presented assessments to the Director of Business Development at Sanofi • Attended global conference calls with regional teams in Europe and Asia • Interacted with vendors providing products to Genzyme, including Kantar, EvaluatePharma, IPSOS, ThomsonOne, IMS, and ZS Consultants • Managed consultants and an intern working with Sanofi to create work directives and timelines for deliverables • Planned, organized, and directed American Society of Clinical Oncology competitive intelligence coverage for Sanofi Oncology • Provided live competitive intelligence coverage at ASCO 2015 in Chicago

MD Class of 2015

Created formamidopyrimidine phosphoramidites for oligonucleotide synthesis to develop DNA standards to elucidate the biochemical changes occurring during carcinogenesis, specifically bis (2-chloroethyl) ethylamine mustard and allyl bromide alklylation at the N-7 position of deoxyguanosine. http://pubs.acs.org/doi/abs/10.1021/tx5002354

The Foundation of Medical Relief of Children (FIMRC) serves the needs of communities in undeveloped areas throughout the world, with an emphasis on care for children. In order to serve in the program, I flew into Kampala and drove into the Ugandan countryside to work at a FIMRC clinic located in Bumwalukani Village. At the clinic, I shadowed doctors, assisted in medical paperwork, organized and dispersed medicine, and assisted in administering testing for HIV. Through following my supervisor as he contacted local authorities and organizations to procure assistance and supplies, I gain insight into the difficulties of administering medical care in underdeveloped areas. Through my experiences in Uganda, I began to see the deeper underlying social and economic factors that prevented proper administration of medical care and aid in underdeveloped areas of the world. My experiences in Uganda led me to explore economics better understand these factors.

I worked under the supervision of Noel Irias at the nascent Carl J. Shapiro Simulation Skills Center in the Beth Israel Deaconess Medical Center (BIDMC) as part of a summer program run by the medical center. The program aimed to expose high school students to various fields of medicine through placement in various departments of the hospital. The Shapiro Simulation Skills center aimed to serve the BIDMC as a learning center for doctors to practice and hone surgical skills through simple instrument manipulation exercises to increase dexterity to equipment that simulated laparoscopic surgical operations. As part of the program, I created presentation for my supervisor explaining various medical procedures and conditions, attained hands on experience with suturing and other medical techniques, and assisted in testing and programming the surgical simulators.